Browsing Tag
Breyanzi
6 posts
The next frontier: Can CAR T therapy become a one-time cure for autoimmune diseases?
Can CAR T therapy move beyond cancer and offer one-time remission for autoimmune disease? A deep look at early data, industry shifts, and clinical implications.
Can Bristol Myers Squibb’s CD19 NEX-T therapy replace lifelong immunosuppression? Early Phase 1 data raises the question
Bristol Myers Squibb’s new CAR T data suggests immune reset potential in lupus, systemic sclerosis, and inflammatory myopathies. Read how the paradigm may shift.
Bristol Myers Squibb Gains U.S. FDA Approval to Remove REMS Programs and Ease Monitoring Rules for Breyanzi and Abecma Cell Therapies
Bristol Myers Squibb gains U.S. FDA approval to remove REMS and reduce monitoring for Breyanzi and Abecma cell therapies, expanding access for blood cancer patients.
FDA grants accelerated approval to Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Bristol Myers Squibb (NYSE: BMY) has announced a significant breakthrough in the treatment of follicular lymphoma with the…
Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials
Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the…
Bristol Myers Squibb gets FDA priority review for Breyanzi sBLA
Bristol Myers Squibb (BMS) has secured priority review from the US Food and Drug Administration (FDA) for its…